Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.554
Buy
RSI(14)
71.514
Buy
STOCH(KDJ)(9,3,3)
81.815
Neutral
ATR(14)
0.932
High Vlolatility
CCI(14)
117.367
Buy
Williams %R
15.513
Overbought
TRIX(12,20)
0.617
Sell
StochRSI(14)
26.046
Sell
Phathom Pharmaceuticals Inc
PHAT17.660USD
+0.410+2.38%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
1.25BMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Phathom Pharmaceuticals Inc
Currency: USD Updated: 2025-12-24Key Insights
Phathom Pharmaceuticals Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 42/158 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 21.78.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Phathom Pharmaceuticals Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
9
analysts
Buy
Current Rating
21.778
Target Price
+46.16%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Phathom Pharmaceuticals Inc Highlights
StrengthsRisks
Phathom Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The Company’s product candidates include VOQUEZNA, VOQUEZNA TRIPLE PAK, and VOQUEZNA DUAL PAK. Its product candidate, VOQUEZNA, contains vonoprazan, an oral small molecule potassium-competitive acid blocker, or potassium-competitive acid blocker (PCAB). PCABs are a novel class of medicines that block acid secretion in the stomach. Vonoprazan has also demonstrated clinical benefits in the treatment of erosive gastroesophageal reflux disease (erosive GERD), and in combination with antibiotics for the treatment of Helicobacter pylori (H. pylori) infection. GERD and H. pylori infection are two of the most common acid-related GI diseases. GERD is a disease that develops when the reflux of acidic stomach contents causes troublesome symptoms and/or complications. H. pylori is a bacterial pathogen.
Growing
The company is in a growing phase, with the latest annual income totaling USD 55.25M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 55.25M.
Undervalued
The company’s latest PE is -4.70, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 60.57M shares, decreasing 28.60% quarter-over-quarter.
Held by PRFDX
Star Investor PRFDX holds 4.14K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.09.
Financial Health
Currency: USD Updated: 2025-12-24The current financial score of Phathom Pharmaceuticals Inc is 8.27, ranking 76/158 in the Pharmaceuticals industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 49.50M, representing a year-over-year increase of 202.74%, while its net profit experienced a year-over-year increase of 64.98%.
Score
Financials
6.16
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.55
Operational Efficiency
10.00
Growth Potential
10.00
Shareholder Returns
7.65
Phathom Pharmaceuticals Inc's Company Valuation
Currency: USD Updated: 2025-12-24The current valuation score of Phathom Pharmaceuticals Inc is 6.25, ranking 129/158 in the Pharmaceuticals industry. Its current P/E ratio is -4.70, which is -90.61% below the recent high of -0.44 and -1.19% above the recent low of -4.76.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 42/158
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2025-12-24The current earnings forecast score of Phathom Pharmaceuticals Inc is 8.44, ranking 36/158 in the Pharmaceuticals industry. The average price target for Phathom Pharmaceuticals Inc is 20.00, with a high of 29.00 and a low of 12.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
9
analysts
Buy
Current Rating
21.778
Target Price
+46.16%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
171
Total
6
Median
8
Average
Company name
Ratings
Analysts
Phathom Pharmaceuticals Inc
PHAT
9
Biogen Inc
BIIB
36
Amgen Inc
AMGN
35
Eli Lilly and Co
LLY
33
Vertex Pharmaceuticals Inc
VRTX
33
AbbVie Inc
ABBV
32
1
2
3
...
34
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2025-12-24The current price momentum score of Phathom Pharmaceuticals Inc is 9.25, ranking 24/158 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 19.27 and the support level at 15.08, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
17.318
Buy
MA10
16.101
Buy
MA20
15.454
Buy
MA50
14.548
Buy
MA100
12.968
Buy
MA200
9.654
Buy
Institutional Confidence
Currency: USD Updated: 2025-12-24The current institutional shareholding score of Phathom Pharmaceuticals Inc is 7.00, ranking 44/158 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 85.19%, representing a quarter-over-quarter decrease of 3.85%. The largest institutional shareholder is The Vanguard, holding a total of 3.22M shares, representing 4.52% of shares outstanding, with 13.96% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
Frazier Life Sciences Management, L.P.
Medicxi Ventures (UK) LLP
Millennium Management LLC
Abingworth Management Limited
Invesco Advisers, Inc.
BlackRock Institutional Trust Company, N.A.
Ensign Peak Advisors, Inc.
New Enterprise Associates (NEA)
683 Capital Management LLC
1
2
Risk Assessment
Currency: USD Updated: 2025-12-24The current risk assessment score of Phathom Pharmaceuticals Inc is 4.99, ranking 77/158 in the Pharmaceuticals industry. The company's beta value is 0.49. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.
Score
Beta vs S&P 500 index
0.49
VaR
+7.05%
240-Day Maximum Drawdown
+68.06%
240-Day Volatility
+115.34%
Return
Best Daily Return
60 days
+8.10%
120 days
+8.77%
5 years
+90.19%
Worst Daily Return
60 days
-6.63%
120 days
-8.62%
5 years
-31.11%
Sharpe Ratio
60 days
+3.83
120 days
+2.79
5 years
+0.24
Risk Assessment
Maximum Drawdown
240 days
+68.06%
3 years
+88.26%
5 years
+94.74%
Return-to-Drawdown Ratio
240 days
+2.27
3 years
+0.44
5 years
-0.13
Skewness
240 days
+5.55
3 years
+4.11
5 years
+2.95
Volatility
Realised Volatility
240 days
+115.34%
5 years
+92.48%
Standardised True Range
240 days
+4.14%
5 years
+5.59%
Downside Risk-Adjusted Return
120 days
+554.08%
240 days
+554.08%
Maximum Daily Upside Volatility
60 days
+56.45%
Maximum Daily Downside Volatility
60 days
+41.56%
Liquidity
Average Turnover Rate
60 days
+3.43%
120 days
+2.91%
5 years
--
Turnover Deviation
20 days
-9.07%
60 days
+92.77%
120 days
+63.48%
Peer Comparison
Pharmaceuticals
Phathom Pharmaceuticals Inc
PHAT
7.74 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Mirum Pharmaceuticals Inc
MIRM
8.81 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Gilead Sciences Inc
GILD
8.78 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Regeneron Pharmaceuticals Inc
REGN
8.75 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Collegium Pharmaceutical Inc
COLL
8.65 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Catalyst Pharmaceuticals Inc
CPRX
8.62 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
FAQs
How does TradingKey generate the Stock Score of Phathom Pharmaceuticals Inc?
The TradingKey Stock Score provides a comprehensive assessment of Phathom Pharmaceuticals Inc based on 34 indicators derived from over 100 underlying data points. These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Phathom Pharmaceuticals Inc’s performance and outlook.
How do we generate the financial health score of Phathom Pharmaceuticals Inc?
To generate the financial health score of Phathom Pharmaceuticals Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns. By integrating these comprehensive data, the financial health score not only reflects Phathom Pharmaceuticals Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Phathom Pharmaceuticals Inc.
How do we generate the company valuation score of Phathom Pharmaceuticals Inc?
To generate the company valuation score of Phathom Pharmaceuticals Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Phathom Pharmaceuticals Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value. By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Phathom Pharmaceuticals Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Phathom Pharmaceuticals Inc.
How do we generate the earnings forecast score of Phathom Pharmaceuticals Inc?
To calculate the earnings forecast score of Phathom Pharmaceuticals Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.Comparing these indicators against peers provides context for the stock’s performance and helps
anchor more realistic expectations.These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Phathom Pharmaceuticals Inc’s future.
How do we generate the price momentum score of Phathom Pharmaceuticals Inc?
When generating the price momentum score for Phathom Pharmaceuticals Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.This comprehensive approach can reflect market sentiment and enable rational forecasts of Phathom Pharmaceuticals Inc’s prices. A higher score indicates a more stable short-term price trend for Phathom Pharmaceuticals Inc.
How do we generate the institutional confidence score of Phathom Pharmaceuticals Inc?
To generate the institutional confidence score of Phathom Pharmaceuticals Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Phathom Pharmaceuticals Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Phathom Pharmaceuticals Inc.
How do we generate the risk management score of Phathom Pharmaceuticals Inc?
To assess the risk management score of Phathom Pharmaceuticals Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.These indicators together provide a multi-dimensional understanding of Phathom Pharmaceuticals Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Phathom Pharmaceuticals Inc.
